Paper Details

  1. Home
  2. Paper Details

Lipid Lowering Therapy: An Era Beyond Statins.

Author: Abdul-RahmanToufik, AhmadShahzaib, AwuahWireko Andrew, BandyopadhyayDhrubajyoti, BukhariSyed Muhammad Awais, CaprilesCamilo Andrés Avendaño, CorrieroAnna Chiara, GoelAkshay, GuptaRahul, HajraAdrija, HerreraEmiliano Cantu, LawrenceJannel, MaresAdriana C, PatelNeal, ShahRohan, ShaikhRaheel, UlusanSebahat, de AndradeHeloisa

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
ReviewAn article that critically examines existing research on a particular topic and summarizes the current state of knowledge in the field.

Overview

This review explores non-statin lipid-lowering therapies, examining recent advances and emerging research. It discusses drugs like bile acid sequestrants, fibrates, nicotinic acid, ezetimibe, and PCSK9 inhibitors, as well as emerging gene-based therapies.
Paper Details　
Original Abstract of the Article :
Dyslipidemia, specifically elevated low-density lipoprotein (LDL) cholesterol levels, causes atherosclerotic cardiovascular disease (ASCVD) and increases the risk of myocardial infarction and stroke. Statins, a class of drugs that exert their effects by inhibiting HMG-CoA reductase, a key enzyme in ...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.cpcardiol.2022.101342

データ提供：米国国立医学図書館（NLM）

Lipid Lowering Therapy: Beyond the Statin Era

Our bodies are like intricate desert ecosystems, with delicate balances that must be maintained. One such balance is cholesterol, a vital component of cell membranes but also a contributor to cardiovascular disease if levels rise too high. This study explores the evolution of lipid-lowering therapy beyond statins, the current mainstay of treatment for dyslipidemia.

Exploring New Horizons in Lipid Lowering Therapy

Statins, by inhibiting HMG-CoA reductase, effectively lower cholesterol levels, but they can also cause side effects like muscle pain. The study provides a comprehensive overview of non-statin lipid-lowering therapies, including bile acid sequestrants, fibrates, nicotinic acid, ezetimibe, and the PCSK9 inhibitors evolocumab and alirocumab. This is like discovering new oases in the desert, offering alternative routes to hydration and sustenance.

Emerging Gene-Based Therapies: A New Frontier

The research also delves into the exciting world of gene-based therapies, using techniques like small interfering RNAs, antisense oligonucleotides, and adeno-associated virus vectors to target lipid metabolism. These innovative therapies hold great promise for the future of dyslipidemia treatment, much like exploring uncharted territories in search of rare and valuable resources.

Dr. Camel's Conclusion

The landscape of lipid-lowering therapy is constantly evolving. While statins remain valuable, the emergence of non-statin therapies provides new options for managing dyslipidemia. Gene-based therapies hold exciting potential for personalized and targeted treatment, offering new hope for those navigating the challenges of high cholesterol.
Date :
  1. Date Completed 2022-11-08
  2. Date Revised 2022-11-08
Further Info :

Pubmed ID

35918009

DOI: Digital Object Identifier

10.1016/j.cpcardiol.2022.101342

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.